CMTM1_v17 is a novel potential therapeutic target in breast cancer

Wang,Jing; Zhang,Guoying; Zhang,Yingmei; Luo,Yang; Song,Quansheng; Qiu,Xiaoyan; Mo,Xiaoning; Wang,Lu

doi:10.3892/or.2014.3429

November-2014 Volume 32 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November-2014 Volume 32 Issue 5

Full Size Image

Article

CMTM1_v17 is a novel potential therapeutic target in breast cancer

Authors:
- Jing Wang
- Guoying Zhang
- Yingmei Zhang
- Yang Luo
- Quansheng Song
- Xiaoyan Qiu
- Xiaoning Mo
- Lu Wang
View Affiliations / Copyright

Affiliations: Department of Immunology, Center for Human Disease Genomics, School of Basic Medical Sciences, Health Science Center, Peking University, Beijing 100191, P.R. China
Pages: 1829-1836
|
Published online on: August 20, 2014

https://doi.org/10.3892/or.2014.3429
Expand metrics +

Abstract

Chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing 1 (CMTM1) consists of at least 23 alternatively spliced isoforms designated CMTM1_v1-v23. In the present study, we detected CMTM1_v17 expression in multiple human normal and tumor tissues and found that CMTM1_v17 was highly expressed in testis and many tumor tissues including breast tumor. The overexpression of CMTM1_v17 in the breast cancer cell line MDA-MB-231 promoted cell proliferation and resistance to tumor necrosis factor-α (TNF-α)-induced apoptosis. Moreover, siRNA-mediated silencing of CMTM1_v17 sensitized MDA-MB-231 cells to TNF-α-induced apoptosis. We propose that CMTM1_v17 may be a novel potential target for therapy in breast cancer patients. The present study provides insight into a novel mechanism by which CMTM1_v17 enhances cellular proliferation and abrogates TNF-α-induced apoptosis. These findings also have implications for clinical practice as they highlight the potential for therapeutic targeting of CMTM1_v17 for the treatment of breast and other cancers in which CMTM1_v17 impacts cellular proliferation and survival.

View Figures

View References

1	Han W, Lou Y, Tang J, et al: Molecular cloning and characterization of chemokine-like factor 1 (CKLF1), a novel human cytokine with unique structure and potential chemotactic activity. Biochem J. 357:127–135. 2001. View Article : Google Scholar : PubMed/NCBI
2	Han W, Ding P, Xu M, et al: Identification of eight genes encoding chemokine-like factor superfamily members 1–8 (CKLFSF1–8) by in silico cloning and experimental validation. Genomics. 81:609–617. 2003.PubMed/NCBI
3	Xia D, Li X, Lou Y, et al: Overexpression of chemokine-like factor 2 promotes the proliferation and survival of C2C12 skeletal muscle cells. Biochim Biophys Acta. 1591:163–173. 2002. View Article : Google Scholar : PubMed/NCBI
4	Lou Y, Xia D, Han W, et al: Molecular cloning and characterization of rat chemokine-like factor 1 and 2. Gene. 307:125–132. 2003. View Article : Google Scholar : PubMed/NCBI
5	Rui M, Xia D, Zhang Y, et al: Molecular cloning and characterization of four isoforms of mCKLF, mouse homologues of human chemokine-like factor. Mol Biol Rep. 30:229–237. 2003. View Article : Google Scholar : PubMed/NCBI
6	Wang L, Wu C, Zheng Y, et al: Molecular cloning and characterization of chemokine-like factor super family member 1 (CKLFSF1), a novel human gene with at least 23 alternative splicing isoforms in testis tissue. Int J Biochem Cell Biol. 36:1492–1501. 2004. View Article : Google Scholar : PubMed/NCBI
7	Di Meo S, Airoldi I, Sorrentino C, Zorzoli A, Esposito S and Di Carlo E: Interleukin-30 expression in prostate cancer and its draining lymph nodes correlates with advanced grade and stage. Clin Cancer Res. 20:585–594. 2014.PubMed/NCBI
8	Shi S, Rui M, Han W, et al: CKLFSF2 is highly expressed in testis and can be secreted into the seminiferous tubules. Int J Biochem Cell Biol. 37:1633–1640. 2005. View Article : Google Scholar : PubMed/NCBI
9	Jin C, Ding P, Wang Y and Ma D: Regulation of EGF receptor signaling by the MARVEL domain-containing protein CKLFSF8. FEBS Lett. 579:6375–6382. 2005. View Article : Google Scholar : PubMed/NCBI
10	Zhong J, Wang Y, Qiu X, et al: Characterization and expression profile of CMTM3/CKLFSF3. J Biochem Mol Biol. 39:537–545. 2006. View Article : Google Scholar : PubMed/NCBI
11	Plate M, Li T, Wang Y, et al: Identification and characterization of CMTM4, a novel gene with inhibitory effects on HeLa cell growth through inducing G2/M phase accumulation. Mol Cells. 29:355–361. 2010. View Article : Google Scholar : PubMed/NCBI
12	Shao L, Cui Y, Li H, et al: CMTM5 exhibits tumor suppressor activities and is frequently silenced by methylation in carcinoma cell lines. Clin Cancer Res. 13:5756–5762. 2007. View Article : Google Scholar
13	Wang Y, Li J, Cui Y, et al: CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. Cancer Res. 69:5194–5201. 2009. View Article : Google Scholar
14	Li H, Li J, Su Y, et al: A novel 3p22.3 gene CMTM7 represses oncogenic EGFR signaling and inhibits cancer cell growth. Oncogene. 33:3109–3118. 2014. View Article : Google Scholar : PubMed/NCBI
15	Liu JC, Voisin V, Bader GD, et al: Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2⁺:ERα⁻ breast cancer. Proc Natl Acad Sci USA. 109:5832–5837. 2012. View Article : Google Scholar
16	Locksley RM, Killeen N and Lenardo MJ: The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 104:487–501. 2001. View Article : Google Scholar : PubMed/NCBI
17	Baldwin AS: Regulation of cell death and autophagy by IKK and NF-κB: critical mechanisms in immune function and cancer. Immunol Rev. 246:327–345. 2012.

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

CMTM1_v17 is a novel potential therapeutic target in breast cancer

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Related Articles